Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, what estimate he has made of the total cost of covid-19 vaccines the UK is planning to receive in (a) 2021 and (b)2022 broken down by manufacturer.

We are not able to disclose details of commercially sensitive contracts between the Government and vaccine manufacturers.

At the Comprehensive Spending Review 2020, the Government announced that more than £6 billion has been made available to develop, manufacture, and procure COVID-19 vaccines.

We have secured early access to 397 million vaccine doses through supply agreements with six separate vaccine developers, of which four have received regulatory approval and three are currently in deployment. This includes agreements with:

• Pfizer/BioNTech for 100 million doses
• University of Oxford/AstraZeneca for 100 million doses
• Moderna for 17 million doses
• Novavax for 60 million doses
• Janssen for 20 million doses
• Valneva for 100 million doses

In addition, the Government has a reservation agreement with GlaxoSmithKline/Sanofi Pasteur for 60 million doses and a non-binding agreement with CureVac for 50 million doses.